Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Investment Research
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
LXRX has been the subject of several other research reports. Citigroup cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their price target for the company from $3.00 to $4.00 in a report on Friday, November 8th. Gabelli lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. They noted that the move was a valuation call. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 25th. Finally, Wedbush reiterated a “buy” rating and set a $17.00 target price on shares of Lexicon Pharmaceuticals in a report on Sunday, December 22nd. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $6.50.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping the consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same period last year, the company posted ($0.26) EPS. The business’s quarterly revenue was up 4124.5% on a year-over-year basis. As a group, equities analysts predict that Lexicon Pharmaceuticals will post 1.01 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. Commonwealth Equity Services LLC boosted its position in Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 4,746 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter worth approximately $202,000. Price T Rowe Associates Inc. MD boosted its position in Lexicon Pharmaceuticals by 77.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock worth $388,000 after acquiring an additional 26,900 shares during the last quarter. AXA boosted its position in Lexicon Pharmaceuticals by 127.2% during the 2nd quarter. AXA now owns 128,600 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 72,000 shares during the last quarter. Finally, Wedbush Securities Inc. boosted its position in Lexicon Pharmaceuticals by 105.1% during the 3rd quarter. Wedbush Securities Inc. now owns 398,684 shares of the biopharmaceutical company’s stock worth $1,200,000 after acquiring an additional 204,345 shares during the last quarter. Hedge funds and other institutional investors own 96.24% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.